InsiderDB

Lobbying disclosures · Lobbying report

ABBV: third_quarter 2026 lobbying report

Patient Access to drug treatment therapies; and drug cost and drug pricing reform. Oversight of the pharmaceutical industry and drug pricing. Policies as they relate to PBMs Issues related to the budget and appropriations process Issues related to the treatment of vitiligo Medicare Part D policies. Monitoring Policies related to the 340b program. Issues related to the implementation of the Inflation Reduction Act Issues related to the budget and appropriations process

Follow ABBV
Became public
Oct 20, 2026, 10:55 PM EDT
Event / period date
Not stated
Collected
Nov 9, 2026, 9:38 AM EST

Why this is connected

Exact legal-name match: AbbVie Inc. (https://www.sec.gov/Archives/edgar/data/1551152/).

Reported lobbying amounts

Income: $50,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/79009122-ec5d-420f-ba74-8cc48049e6a0/","filing_uuid":"79009122-ec5d-420f-ba74-8cc48049e6a0","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/79009122-ec5d-420f-ba74-8cc48049e6a0/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Paul A. Brathwaite","dt_posted":"2026-10-20T22:55:11-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1220 L Street, NW","registrant_address_2":"Suite 100-401","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":401104703,"url":"https://lda.gov/api/v1/registrants/401104703/","house_registrant_id":null,"name":"FEDERAL STREET STRATEGIES, LLC","description":"Government relations and public policy consulting firm","address_1":"1220 L Street, NW","address_2":"Suite 100-401","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"PAUL BRATHWAITE","contact_telephone":"+1 202-274-1099","dt_updated":"2026-07-30T23:17:42.705814-04:00"},"client":{"id":202415,"url":"https://lda.gov/api/v1/clients/202415/","client_id":125,"name":"ABBVIE, INC.","general_description":"Biopharmaceutical Research & Development Company.","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"IL","ppb_state_display":"Illinois","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2019-01-11"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Patient Access to drug treatment therapies; and drug cost and drug pricing reform. Oversight of the pharmaceutical industry and drug pricing. Policies as they relate to PBMs Issues related to the budget and appropriations process Issues related to the treatment of vitiligo","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67337,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"BRATHWAITE","suffix":null,"suffix_display":null},"covered_position":"Executive Director, Congressional Black Caucus; Deputy Assistant Secretary, ESA, U.S. Department of Labor; Special Assistant to the Secretary, U.S. Department of Labor.","new":false},{"lobbyist":{"id":142566,"prefix":null,"prefix_display":null,"first_name":"VEN","nickname":null,"middle_name":null,"last_name":"NERALLA","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, U.S. Rep. Andy Levin; Deputy Chief of Staff, U.S. Rep. Pramila Jayapal; Legislative Director, U.S. Rep. Barbara Lee; Legislative Assistant, U.S. Rep. Peter DeFazio; Senior Advisor, USDA; OPP; and MCC.","new":true},{"lobbyist":{"id":147905,"prefix":null,"prefix_display":null,"first_name":"STACEY","nickname":null,"middle_name":null,"last_name":"LEAVANDOSKY","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, U.S. Representative Zoe Lofgren; Senior Advisor, Committee on Science, Space & Technology; Senior Advisor, Committee on House Administration; Executive Director, California Democratic Congressional Delegation","new":true},{"lobbyist":{"id":147906,"prefix":null,"prefix_display":null,"first_name":"KAADE","nickname":null,"middle_name":null,"last_name":"WALLACE","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent, U.S. Senator Amy Klobuchar; Staff Assistant, U.S. Representative Betty McCollum","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare Part D policies. Monitoring Policies related to the 340b program. Issues related to the implementation of the Inflation Reduction Act Issues related to the budget and appropriations process","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67337,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"BRATHWAITE","suffix":null,"suffix_display":null},"covered_position":"Executive Director, Congressional Black Caucus; Deputy Assistant Secretary, ESA, U.S. Department of Labor; Special Assistant to the Secretary, U.S. Department of Labor.","new":false},{"lobbyist":{"id":142566,"prefix":null,"prefix_display":null,"first_name":"VEN","nickname":null,"middle_name":null,"last_name":"NERALLA","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, U.S. Rep. Andy Levin; Deputy Chief of Staff, U.S. Rep. Pramila Jayapal; Legislative Director, U.S. Rep. Barbara Lee; Legislative Assistant, U.S. Rep. Peter DeFazio; Senior Advisor, USDA; OPP; and MCC.","new":true},{"lobbyist":{"id":147905,"prefix":null,"prefix_display":null,"first_name":"STACEY","nickname":null,"middle_name":null,"last_name":"LEAVANDOSKY","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, U.S. Representative Zoe Lofgren; Senior Advisor, Committee on Science, Space & Technology; Senior Advisor, Committee on House Administration; Executive Director, California Democratic Congressional Delegation","new":true},{"lobbyist":{"id":147906,"prefix":null,"prefix_display":null,"first_name":"KAADE","nickname":null,"middle_name":null,"last_name":"WALLACE","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent, U.S. Senator Amy Klobuchar; Staff Assistant, U.S. Representative Betty McCollum","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Price change after we could observe it

+0.37% ABBV

Adjusted closing prices from Nov 10, 2026 to Nov 11, 2026. SPY changed 1.32% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.

Congressional trading in ABBV

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.